Drug
Carisbamate clinical trials
Also written RWJ-333369 and YKP509.
- studies test it
- 21
- open now
- 1
- in phase 3
- 9
- first study started
- 2002
Keep track of what changes. Save the carisbamate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
21 studies that test it; most in 2007 (6)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 6 |
| 2008 | 1 |
| 2009 | 3 |
| 2013 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 9
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 1
Studies
Open first, then newest update. How each study uses carisbamate is read from its arms, and is right about nine times in ten.
Testing it · 21
- Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and AdultsRecruitingPhase 3SK Life Science, Inc.NCT05219617Written as Carisbamate
- Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut SyndromeCompletedPhase 1SK Life Science, Inc.NCT04062981Written as Carisbamate
- Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut SyndromeCompletedPhase 1SK Life Science, Inc.NCT03731715Written as Carisbamate
- Bioavailability and Food Effect Study of 3 Types of CarisbamateCompletedPhase 1SK Life Science, Inc.NCT04520360Written as Carisbamate
- Carisbamate as a Potential Treatment for Alcohol DependenceCompletedPhase 1/2Baylor College of MedicineNCT02435381Written as Carisbamate
- An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).CompletedPhase 2SK Life Science, Inc.NCT00492323Written as carisbamate
- Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).CompletedPhase 2SK Life Science, Inc.NCT00501202Written as RWJ-333369 (carisbamate)
- An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset SeizuresCompletedPhase 3SK Life Science, Inc.NCT00744731Written as carisbamate
- An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.CompletedPhase 3SK Life Science, Inc.NCT00991757Written as carisbamate
- Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.TerminatedPhase 3SK Life Science, Inc.NCT00563459Written as carisbamate
- An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With EpilepsyCompletedPhase 2SK Life Science, Inc.NCT00210522Written as RWJ 333369
- A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.CompletedPhase 3SK Life Science, Inc.NCT00740623Written as Carisbamate
- An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With EpilepsyCompletedPhase 2SK Life Science, Inc.NCT00210652Written as RWJ 333369:
- A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential TremorCompletedPhase 2SK Life Science, Inc.NCT00524056Written as Carisbamate
- An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in DiabeticsCompletedPhase 2SK Life Science, Inc.NCT00870454Written as Carisbamate 800 mg/d
- Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset SeizuresTerminatedPhase 3SK Life Science, Inc.NCT00697762Written as RWJ-333369
- Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset SeizuresCompletedPhase 3SK Life Science, Inc.NCT00697918Written as RWJ-333369
- Safety and Efficacy of 333369 in the Treatment of Partial EpilepsyCompletedPhase 2SK Life Science, Inc.NCT00228969Written as RWJ-333369
- A Study of the Efficacy of RWJ-333369 in the Prevention of MigraineCompletedPhase 2SK Life Science, Inc.NCT00109083Written as RWJ-333369
- A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.CompletedPhase 3SK Life Science, Inc.NCT00425282Written as RWJ-333369
Codes
What other systems call carisbamate · ClinicalTrials.gg INT005068
- UNII (FDA) P7725I9V3ZCARISBAMATEConfirmed FDA, Wikidata
- Wikidata Q76393597carisbamateConfirmed FDA, Wikidata
- NCI Thesaurus C75161CarisbamateOne source FDA
- DrugBank DB12338One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P7725I9V3Z | CARISBAMATE | Confirmed FDA, Wikidata |
| Wikidata | Q76393597 | carisbamate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C75161 | Carisbamate | One source FDA |
| DrugBank | DB12338 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.